Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2209–2232 of 2,670 matching trials from the live ClinicalTrials.gov search.

Filters: Sponsor: University of San Francisco Clear all

Conditions: HIV (Human Immunodeficiency Virus)
Interventions: Lump sum, Monthly installments, Choice; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Keratoconus
Interventions: Dextenza 0.4Mg Ophthalmic Insert, topical prednisolone acetate 1% (PredForte) eye drops; Drug
Lead sponsor: Maanasa Indaram, MD; Other
Eligibility: 13 Years to 64 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: San Francisco, California

Conditions: Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent WHO Grade III Glioma, WHO Grade III Glioma
Interventions: ONC201, Radiation Therapy, Paxalisib, DNX-2401; Drug · Radiation
Lead sponsor: University of California, San Francisco; Other
Eligibility: 2 Years to 39 Years
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 19
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 16 more

Conditions: Castrate Resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Prostate Cancer, Prostate Carcinoma
Interventions: Pembrolizumab, 177Lu-PSMA-617; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Male only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Migraine
Interventions: Galcanezumab; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Major Depressive Disorder
Interventions: Mindfulness Based Cognitive Therapy, Health Enhancement Program and medication management; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: San Francisco, California

Conditions: CNS Lymphoma, Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma
Interventions: Tafasitamab, Lenalidomide; Drug
Lead sponsor: James Rubenstein; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Encephalopathy, Birth Defect, Intellectual Disability, Multiple Congenital Anomaly, Metabolic Disease, Epilepsy, Neuro-Degenerative Disease, Cerebral Palsy, Developmental Delay, Developmental Defect
Interventions: Whole Exome Sequencing; Diagnostic Test
Lead sponsor: University of California, San Francisco; Other
Eligibility: Up to 25 Years
Enrollment: 529 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 4
States / cities: Fresno, California • Oakland, California • San Francisco, California

Conditions: Lung Cancer
Interventions: bevacizumab, carboplatin, docetaxel, conventional surgery; Biological · Drug · Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Hereditary Hemorrhagic Telangiectasia, Arteriovenous Malformations, Telangiectasia, Epistaxis, GastroIntestinal Bleeding, Cerebral Arteriovenous Malformations, Vascular Malformation
Interventions: Not listed
Lead sponsor: Cure HHT; Other
Eligibility: Not listed
Enrollment: 10,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2033
U.S. locations: 16
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 13 more

Conditions: Pregnant Individuals Requesting Standard Microarray
Interventions: Genomic Sequencing; Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 64 Years
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Type 2 Diabetes
Interventions: Standard of Care, Shared Medical Appointments; Other · Behavioral
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 12 Years to 18 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Los Angeles, California • San Francisco, California

Conditions: Adolescent Idiopathic Scoliosis (AIS), Neuromuscular Scoliosis, Adolescent Idiopathic Scoliosis
Interventions: Ropivacaine Hydrocloride; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 10 Years to 18 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Migraine, Chronic Migraine
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Acute Ischemic Stroke
Interventions: Cranial Accelerometry Measurement; Diagnostic Test
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Demyelinating Diseases, Demyelination; Corpus Callosum, Multiple Sclerosis Brain Lesion, Multiple Sclerosis Acute and Progressive, Clinically Isolated Syndrome, CNS Demyelinating
Interventions: Clemastine Fumarate, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 55 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Interventions: Tamsulosin, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 55 Years to 80 Years · Male only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Glioblastoma
Interventions: Not listed
Lead sponsor: Larissa University Hospital; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Anorexia Nervosa
Interventions: Narrative Medicine (NM) Workshop Series; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 16 Years to 25 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Stable Plaque Psoriasis
Interventions: Ultravate ointment twice daily + LacHydrin lotion twice daily, Ultravate ointment once daily + LacHydrin lotion twice daily; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Freezing of Gait Symptoms in Parkinson Disease
Interventions: Active Stimulation, Sham (No Treatment); Device
Lead sponsor: Iahn Cajigas; Other
Eligibility: 35 Years to 80 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: San Francisco, California • Miami, Florida • Philadelphia, Pennsylvania

Conditions: Aging, MCI, Cognitive Decline
Interventions: MediTrain, Worder; Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 60 Years to 99 Years
Enrollment: 4,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Cancer
Interventions: Questionnaires; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Postmenopause
Interventions: 0.25mg DRSP / 0.5mg E2 (BAY86-4891), 0.5mg NETA / 1.0mg E2 (Activella); Drug
Lead sponsor: Bayer; Industry
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 662 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 17
States / cities: Chandler, Arizona • San Diego, California • Denver, Colorado + 13 more

Search by objective public record fields.

Guaranteed Income to Boost HIV Care Continuity and Suppression Post-Jail Release

Dextenza Versus Topical Steroid Eye Drops for Postoperative Management Following Corneal Crosslinking

Combination Therapy for the Treatment of Diffuse Midline Gliomas

Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer

Emgality for Migraine in Breastmilk

Practicing Alternative Techniques to Heal From Depression: The PATH-D Study

Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma

Clinical Utility of Pediatric Whole Exome Sequencing

Docetaxel, Carboplatin, and Bevacizumab in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery

Comprehensive HHT Outcomes Registry of the United States (CHORUS)

Genomic Sequencing in Anatomically Normal Fetuses

Implementation of Team Clinic for Type 2 Diabetes (TCT2)

The Effect of Erector Spinae Plane Block (ESPB) on Pediatric Pain Management Following Posterior Spinal Fusion (PSF) Surgery

Neuroimaging Studies of Chronic Primary Headaches Using Positron Emission Tomography and Magnetic Resonance Imaging

Head Pulse for Ischemic Stroke Detection

Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a Myelin Repair Therapy

Deprescribing Tamsulosin in Older Men

A Multicenter, Prospective Study for Glioblastoma Patients

Incorporating Narrative Into the Treatment of Youth With Anorexia Nervosa (Virtual)

Comparing the Efficacy of Ultravate Ointment in Combination With Lac-Hydrin Lotion in the Treatment of Psoriasis

CnF-DBS for Levodopa-Resistant FOG

Enhancing Attention and Wellbeing Using Digital Therapeutics

Evaluation of Survivorship Wellness Group Program for Patients Treated at University of California, San Francisco (UCSF)

Endometrial Safety Study